Investor Presentation First Nine Months of 2023
14
Investor presentation
First nine months of 2023
R&D milestones
Clinical milestones¹
Project
Diabetes care
Q3 2023
Oral semaglutide (25/50mg)
Cagrisema T2D
Q4 2023
✓
EU submission
✓ Phase 3 initiation
IcoSema
Obesity care
FLOW kidney outcomes trial
Oral semaglutide (25/50 mg)
SELECT CVOT
STEP HFPEF
Oral Amycretin
Sc. Amycretin
EU/US Submission
✓ Phase 3 results
Phase 3 results (T2D)
Phase 1 results
Rare disease
Nedosiran
Concizumab
Phase 1 initiation
✓ US approval
✓ JP approval (HAWI/HBWI)
Mim8
Other serious chronic diseases
ANGPTL3i
✓ Phase 1 initiation
Novo NordiskⓇ
Regulatory milestones¹
H1 2024
Phase 3 results
Phase 3 results
Phase 3 results (OASIS 4)
Phase 3 results
1Expected to be published in the given quarter or in the subsequent quarterly company announcement
CVOT: Cardiovascular Outcomes Trial; EU: European Union; HFPEF: Heart failure with preserved ejection fraction; T2D: Type 2 Diabetes; US: United States; ANGPTL3i: Angiopoietin-like protein 3 inhibitor; Sc.: Subcutaneous; JP: Japan; HAWI/HBWI: Haemophilia A/B
with inhibitorsView entire presentation